Literature DB >> 10639353

Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.

R F Pfeltz1, V K Singh, J L Schmidt, M A Batten, C S Baranyk, M J Nadakavukaren, R K Jayaswal, B J Wilkinson.   

Abstract

A series of 12 Staphylococcus aureus strains of various genetic backgrounds, methicillin resistance levels, and autolytic activities were subjected to selection for the glycopeptide-intermediate S. aureus (GISA) susceptibility phenotype on increasing concentrations of vancomycin. Six strains acquired the phenotype rapidly, two did so slowly, and four failed to do so. The vancomycin MICs for the GISA strains ranged from 4 to 16 microg/ml, were stable to 20 nonselective passages, and expressed resistance homogeneously. Neither ease of acquisition of the GISA phenotype nor the MIC attained correlated with methicillin resistance hetero- versus homogeneity or autolytic deficiency or sufficiency. Oxacillin MICs were generally unchanged between parent and GISA strains, although the mec members of both isogenic methicillin-susceptible and methicillin-resistant pairs acquired the GISA phenotype more rapidly and to higher MICs than did their susceptible counterparts. Transmission electron microscopy revealed that the GISA strains appeared normal in the absence of vancomycin but had thickened and diffuse cell walls when grown with vancomycin at one-half the MIC. Common features among GISAs were reduced doubling times, decreased lysostaphin susceptibilities, and reduced whole-cell and zymographic autolytic activities in the absence of vancomycin. This, with surface hydrophobicity differences, indicated that even in the absence of vancomycin the GISA cell walls differed from those of the parents. Autolytic activities were further reduced by the inclusion of vancomycin in whole-cell and zymographic studies. The six least vancomycin-susceptible GISA strains exhibited an increased capacity to remove vancomycin from the medium versus their parent lines. This study suggests that while some elements of the GISA phenotype are strain specific, many are common to the phenotype although their expression is influenced by genetic background. GISA strains with similar glycopeptide MICs may express individual components of the phenotype to different extents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639353      PMCID: PMC89674          DOI: 10.1128/AAC.44.2.294-303.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.

Authors:  H Hanaki; H Labischinski; Y Inaba; N Kondo; H Murakami; K Hiramatsu
Journal:  J Antimicrob Chemother       Date:  1998-09       Impact factor: 5.790

2.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

3.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin.

Authors:  E Debbia; P E Varaldo; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

5.  Resistance of Staphylococcus aureus to penicillins and cephalosporins: reversal of intrinsic resistance with some chelating agents.

Authors:  L D Sabath; S J Wallace; K Byers; I Toftegaard
Journal:  Ann N Y Acad Sci       Date:  1974-07-31       Impact factor: 5.691

6.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

7.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

Review 8.  Molecular aspects of methicillin resistance in Staphylococcus aureus.

Authors:  H de Lencastre; B L de Jonge; P R Matthews; A Tomasz
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

9.  Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.

Authors:  F Biavasco; E Giovanetti; M P Montanari; R Lupidi; P E Varaldo
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

10.  Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.

Authors:  W C Noble; Z Virani; R G Cree
Journal:  FEMS Microbiol Lett       Date:  1992-06-01       Impact factor: 2.742

View more
  54 in total

1.  Structural and topological differences between a glycopeptide-intermediate clinical strain and glycopeptide-susceptible strains of Staphylococcus aureus revealed by atomic force microscopy.

Authors:  S Boyle-Vavra; J Hahm; S J Sibener; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance.

Authors:  Susan Boyle-Vavra; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

3.  Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains.

Authors:  Arunachalam Muthaiyan; Radheshyam K Jayaswal; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

4.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

6.  Transcriptomic and functional analysis of an autolysis-deficient, teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.

Authors:  Adriana Renzoni; Christine Barras; Patrice François; Yvan Charbonnier; Elzbieta Huggler; Christian Garzoni; William L Kelley; Paul Majcherczyk; Jacques Schrenzel; Daniel P Lew; Pierre Vaudaux
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

7.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 8.  [Antibacterial photodynamic therapy. A new treatment for superficial bacterial infections?].

Authors:  T Maisch; R-M Szeimies; N Lehn; C Abels
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

9.  Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors:  Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal:  Int J Antimicrob Agents       Date:  2009-02-23       Impact factor: 5.283

10.  Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus.

Authors:  J E Finan; G L Archer; M J Pucci; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.